文献速递白血病

半胱氨酸结合佐剂可提高急性髓系白血病小鼠模型的生存率并促进免疫功能

Cysteine-binding adjuvant enhances survival and promotes immune function in a murine model of acute myeloid leukemia.
PubMed 文献 · Blood Adv · 2024-01-01

研究探索一种抗原无关的聚合物体内癌症疫苗平台,利用癌细胞表面游离半胱氨酸硫醇增多(阿糖胞苷处理后进一步增加)的特性,通过吡啶二硫化物(PDS)基团共价偶联至癌细胞表面及碎片,并在静脉给药后靶向肝脏和脾脏的抗原提呈细胞,引发T细胞活化和抗体生成,最终延长荷瘤小鼠生存。

要点

  • 该平台利用癌细胞代谢和酶失调导致表面游离半胱氨酸硫醇过剩的特性实现原位共价连接。
  • 阿糖胞苷处理可增加癌细胞表面硫醇丰度,增强PDS功能化聚合物的偶联效率。
  • 静脉给药后,PDS功能化共聚物靶向肝脏和脾脏抗原提呈细胞,引发抗癌免疫反应。

核心结论

  • 抗原无关的聚合物体内癌症疫苗平台可在急性髓系白血病小鼠模型中引发抗癌免疫反应并延长生存。

研究设计与样本

  • 研究采用小鼠急性髓系白血病模型,评估抗原无关的聚合物体内癌症疫苗平台。

主要发现

  • 癌细胞表面游离半胱氨酸硫醇在阿糖胞苷处理后丰度增加,可与PDS基团发生二硫交换实现共价附着。
  • PDS功能化单体与甘露糖基团及TLR7激动剂共聚物静脉给药后靶向肝脏和脾脏的抗原提呈细胞。
  • 该化合物引发T细胞活化和抗体生成,最终延长荷瘤小鼠生存。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Therapeutic vaccination has long been a promising avenue for cancer immunotherapy but is often limited by tumor heterogeneity. The genetic and molecular diversity between patients often results in variation in the antigens present on cancer cell surfaces. As a result, recent research has focused on personalized cancer vaccines. Although promising, this strategy suffers from time-consuming production, high cost, inaccessibility, and targeting of a limited number of tumor antigens. Instead, we explore an antigen-agnostic polymeric in situ cancer vaccination platform for treating blood malignancies, in our model here with acute myeloid leukemia (AML). Rather than immunizing against specific antigens or targeting adjuvant to specific cell-surface markers, this platform leverages a characteristic metabolic and enzymatic dysregulation in cancer cells that produces an excess of free cysteine thiols on their surfaces. These thiols increase in abundance after treatment with cytotoxic agents such as cytarabine, the current standard of care in AML. The resulting free thiols can undergo efficient disulfide exchange with pyridyl disulfide (PDS) moieties on our construct and allow for in situ covalent attachment to cancer cell surfaces and debris. PDS-functionalized monomers are incorporated into a statistical copolymer with pendant mannose groups and TLR7 agonists to target covalently linked antigen and adjuvant to antigen-presenting cells in the liver and spleen after IV administration. There, the compound initiates an anticancer immune response, including T-cell activation and antibody generation, ultimately prolonging survival in cancer-bearing mice.

来源:Blood Adv,查看原文。版权归原作者所有。

引用

  1. Slezak AJ, Chang K, Beckman TN, et al. Cysteine-binding adjuvant enhances survival and promotes immune function in a murine model of acute myeloid leukemia. Blood Adv. 2024. PMID: 38324726. doi:10.1182/bloodadvances.2023012529

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。